Equipoise, at a glance

People seek Equipoise, or EQ, for gradual muscle gain, a fuller, more vascular look and sometimes a bigger appetite. It is a long-acting form of boldenone.

The practical trade-off is slow release alongside blood-count concerns. Hunger and visible gains are not predictable, and a lean appearance cannot tell you what is happening in your bloodwork.

Reported doses & duration Blood-count concerns

What draws people to EQ?

The appeal What to weigh
Gradual size Muscle, strength and fullness. No reliable timetable for visible results.
More appetite Easier eating during a bulk. Some report more hunger; others do not.
Leaner look Visible veins and less perceived puffiness. Appearance does not show blood pressure or hematocrit.
Sought effects and reported experiences, not guaranteed benefits.

Reported doses and how long people use it

200–600 mg per week is the male boldenone undecylenate range in Mullen and colleagues’ published compilation. It describes amounts promoted in online user and supplier material, not a studied or recommended regimen.

That is a weekly total, not an amount per injection. The table gives no injection split or course length. Claims that EQ “needs a long cycle” do not establish an effective or safe duration, and a slow release profile is not a reason to extend use.

Does EQ reliably increase appetite?

No dependable human appetite effect is established by the sources here. Some people describe strong hunger; others notice little change. The same uncertainty applies to claims of a uniquely “clean” gain in muscle or better endurance: reports usually involve training, diet and other drugs, so they cannot isolate EQ’s contribution.

Equipoise is associated with boldenone undecylenate. The current US veterinary regulation covers use in debilitated horses when improved weight or physical condition is desired. That is not evidence for appetite treatment or bodybuilding results in healthy adults.

Blood counts: what matters

Hematocrit is the proportion of blood occupied by red blood cells. It is a laboratory measurement, not something you can judge from vascularity, endurance or how you feel. A high result needs assessment of its cause; hydration, smoking, other medicines and medical conditions can affect the picture. NHS: erythrocytosis

In the 100-man HAARLEM study, mixed androgen use was associated with higher hematocrit, higher blood pressure and less favorable cholesterol measurements. It did not isolate boldenone or show that EQ raises hematocrit more than every other steroid. Original prospective study

Bring the full drug history and previous blood results to a clinician if a value is elevated. Blood donation does not replace investigating a recurring high result, and a normal hematocrit does not establish normal blood pressure or cholesterol.

Slow release is not a gains timetable

An injection can continue releasing after the last dose, but drug release, visible gains and recovery are different timelines. A curve cannot tell you when muscle growth will become noticeable or when natural hormone production has recovered.

The familiar 14-day human half-life is an assumption in this site’s EQ model, not a measured value established by the cited studies. Soma and colleagues measured boldenone in horses, reporting a median elimination half-life of 123 hours after intramuscular administration. That animal result cannot be substituted for a human half-life. Soma et al., 2007

The EQ compound page explains the relative timing model. It illustrates overlap using assumed timing; it does not predict human blood concentrations, a safe stopping point or a recovery-medication schedule.

Can EQ replace an aromatase inhibitor?

The sources here do not establish EQ as a reliable estrogen-control treatment or a fixed ratio of EQ to testosterone. Reports of low estrogen, anxiety or libido changes do not establish the cause or tell you how to adjust another drug. An assumed percentage of testosterone’s aromatization cannot determine an AI dose.

Symptoms, laboratory findings and the full drug history need interpretation together. For the broader question, see aromatase inhibitor timing.

Common questions

Is EQ a bulking or cutting drug? People seek it for both gradual size and a leaner look. Neither label establishes a predictable result; more hunger may also conflict with trying to eat less.

Is boldenone cypionate interchangeable with Equipoise? No. It is a different ester, and its human release profile and dose equivalence are not established here. Record the full ingredient name when discussing exposure with a clinician.

How does it compare with Deca? The human release evidence is much stronger for nandrolone esters. Nandrolone vs boldenone explains the practical comparison without assuming equal doses produce equal effects.

Is there a reliable detection countdown? The sources here do not establish a universal human deadline. Urine detection and the drug’s release profile are different measurements.

Sources and review notes

Checked October 11, 2026. Reported-use amounts, veterinary evidence and human studies of mixed androgen use answer different questions.